NET LOSS PER SHARE (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2021 |
Dec. 31, 2020 |
Schedule of basic and diluted net loss per share |
Schedule of earning per share |
|
|
|
|
|
|
|
|
For the Three |
|
|
For the Six |
|
|
|
Months Ended |
|
|
Months Ended |
|
|
|
June 30, 2021 |
|
|
June 30, 2021 |
|
Common stock subject to possible redemption |
|
|
|
|
|
|
|
|
Numerator: Net income allocable to common stock subject to possible redemption amortized interest income on marketable securities held in trust |
|
$ |
3,151 |
|
|
$ |
11,723 |
|
Less: interest available to be withdrawn for payment of taxes |
|
|
(3,151 |
) |
|
|
(11,723 |
) |
Net income allocable to common stock subject to possible redemption |
|
$ |
- |
|
|
$ |
- |
|
Denominator: Weighted average redeemable common stock, basic and diluted |
|
|
9,822,956 |
|
|
|
9,673,135 |
|
Basic and diluted net income per share, redeemable common stock |
|
$ |
0.00 |
|
|
$ |
0.00 |
|
|
|
|
|
|
|
|
|
|
Non-redeemable common stock |
|
|
|
|
|
|
|
|
Numerator: Net loss minus redeemable net earnings |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(7,705,427 |
) |
|
$ |
(4,662,223 |
) |
Redeemable net earnings |
|
|
- |
|
|
|
- |
|
Non-redeemable net loss |
|
$ |
(7,705,427 |
) |
|
$ |
(4,662,223 |
) |
Denominator: Weighted average non-redeemable common stock, basic and diluted |
|
|
5,097,044 |
|
|
|
5,246,865 |
|
Basic and diluted net loss per share, common stock |
|
$ |
(1.51 |
) |
|
$ |
(0.89 |
) |
|
Schedule of earning per share |
|
|
|
|
|
|
For the Period from |
|
|
|
August 20, 2020 (Inception) |
|
|
|
through December 31, 2020 |
|
Common stock subject to possible redemption |
|
|
|
|
Numerator: Net income allocable to common stock subject to possible redemption Amortized Interest income on marketable securities held in trust |
|
$ |
7,960 |
|
Less: interest available to be withdrawn for payment of taxes |
|
|
(7,960 |
) |
Net income allocable to common stock subject to possible redemption |
|
$ |
— |
|
Denominator: Weighted Average Redeemable common stock Redeemable Common Stock, Basic and Diluted |
|
|
3,399,685 |
|
Basic and Diluted net income per share, Redeemable Common Stock |
|
$ |
0.00 |
|
|
|
|
|
|
Non-Redeemable Common Stock |
|
|
|
|
Numerator: Net Income minus Redeemable Net Earnings |
|
|
|
|
Net Income |
|
$ |
4,092,424 |
|
Redeemable Net Earnings |
|
|
— |
|
Non-Redeemable Net Income |
|
$ |
4,092,424 |
|
Denominator: Weighted Average Non-Redeemable Common Stock Basic and diluted weighted average shares outstanding, common stock |
|
|
4,646,706 |
|
Basic and diluted net income per share, common stock |
|
$ |
0.88 |
|
|
Schedule of anti-dilutive net loss per share |
|
Schedule of computation of diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
|
2020 |
|
|
2019 |
|
Stock options outstanding (a) |
|
|
958,782 |
|
|
|
888,621 |
|
Non-vested shares of restricted stock |
|
|
68,557 |
|
|
|
14,200 |
|
Preferred stock and warrants (b): |
|
|
|
|
|
|
|
|
Convertible Preferred Stock |
|
|
|
|
|
|
|
|
Series B |
|
|
— |
|
|
|
72,123 |
|
Series B-1 |
|
|
72,123 |
|
|
|
— |
|
Series C |
|
|
— |
|
|
|
416,667 |
|
Series C-1 |
|
|
416,667 |
|
|
|
— |
|
Series D |
|
|
1,080,993 |
|
|
|
1,450,993 |
|
Series D-1 |
|
|
325,203 |
|
|
|
325,203 |
|
Series D-2 |
|
|
370,000 |
|
|
|
— |
|
Senior Convertible Preferred Stock |
|
|
|
|
|
|
|
|
Series E |
|
|
615,231 |
|
|
|
615,231 |
|
Series E-1 |
|
|
393,511 |
|
|
|
393,511 |
|
Series F |
|
|
352,076 |
|
|
|
352,076 |
|
Series F-1 |
|
|
46,325 |
|
|
|
46,325 |
|
Series G |
|
|
740,987 |
|
|
|
— |
|
Series H |
|
|
168,288 |
|
|
|
— |
|
Warrants |
|
|
|
|
|
|
|
|
Series D and D-1 warrants |
|
|
365,854 |
|
|
|
365,854 |
|
Series H warrants |
|
|
139,428 |
|
|
|
— |
|
|
Airspan [Member] |
|
|
Schedule of basic and diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule of basic and diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(10,418 |
) |
|
$ |
(11,053 |
) |
|
$ |
(23,967 |
) |
|
$ |
(24,068 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator - basic and diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
670,043 |
|
|
|
669,534 |
|
|
|
669,839 |
|
|
|
669,534 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share - basic and diluted |
|
$ |
(15.55 |
) |
|
$ |
(16.51 |
) |
|
$ |
(35.78 |
) |
|
$ |
(35.95 |
) |
|
Schedule of computation of basic and diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
|
2020 |
|
|
2019 |
|
|
2018 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(25,643 |
) |
|
$ |
(51,981 |
) |
|
$ |
(35,292 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator – basic and diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
669,534 |
|
|
|
669,534 |
|
|
|
254,679 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share – basic and diluted |
|
$ |
(38.30 |
) |
|
$ |
(77.64 |
) |
|
$ |
(138.57 |
) |
|
Schedule of anti-dilutive net loss per share |
Schedule of anti-dilutive net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Stock options outstanding (a) |
|
|
1,018,125 |
|
|
|
980,946 |
|
|
|
1,018,125 |
|
|
|
980,946 |
|
Non-vested shares of restricted stock |
|
|
72,989 |
|
|
|
68,557 |
|
|
|
72,989 |
|
|
|
68,557 |
|
Preferred stock and warrants (b): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series B |
|
|
— |
|
|
|
72,123 |
|
|
|
— |
|
|
|
72,123 |
|
Series B-1 |
|
|
72,123 |
|
|
|
— |
|
|
|
72,123 |
|
|
|
— |
|
Series C |
|
|
— |
|
|
|
416,667 |
|
|
|
— |
|
|
|
416,667 |
|
Series C-1 |
|
|
416,667 |
|
|
|
— |
|
|
|
416,667 |
|
|
|
— |
|
Series D |
|
|
1,080,993 |
|
|
|
1,450,993 |
|
|
|
1,080,993 |
|
|
|
1,450,993 |
|
Series D-1 |
|
|
325,203 |
|
|
|
325,203 |
|
|
|
325,203 |
|
|
|
325,203 |
|
Series D-2 |
|
|
370,000 |
|
|
|
— |
|
|
|
370,000 |
|
|
|
— |
|
Senior Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series E |
|
|
615,231 |
|
|
|
615,231 |
|
|
|
615,231 |
|
|
|
615,231 |
|
Series E-1 |
|
|
393,511 |
|
|
|
393,511 |
|
|
|
393,511 |
|
|
|
393,511 |
|
Series F |
|
|
352,076 |
|
|
|
352,076 |
|
|
|
352,076 |
|
|
|
352,076 |
|
Series F-1 |
|
|
46,325 |
|
|
|
46,325 |
|
|
|
46,325 |
|
|
|
46,325 |
|
Series G |
|
|
740,987 |
|
|
|
464,566 |
|
|
|
740,987 |
|
|
|
464,566 |
|
Series H |
|
|
181,294 |
|
|
|
— |
|
|
|
181,294 |
|
|
|
— |
|
Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series D and D-1 warrants |
|
|
162,602 |
|
|
|
585,624 |
|
|
|
162,602 |
|
|
|
585,624 |
|
Series H warrants |
|
|
145,931 |
|
|
|
— |
|
|
|
145,931 |
|
|
|
— |
|
|
(a) |
If the Company had reported net income, the calculation of these per share amounts would have included the dilutive effect of these common stock equivalents using the treasury stock method for stock options. |
|
(b) |
The convertible preferred stock and warrants referred to in Note [11] were also excluded on an as converted basis because their effect would have been anti-dilutive. |
|
|